Koninklijke Philips is a Dutch health-technology group whose second-quarter print tests whether the post-Respironics rebuild is earning its keep or whether a one-time customs refund is doing the work. Comparable sales rose across all three segments, and management left the full-year growth range unchanged. The margin expansion and the raised cash-flow outlook sit almost entirely on a United States tariff refund booked as a cost-of-sales credit. Strip that credit out and adjusted operating profit slipped a little as inflation and remaining duties offset productivity.
The refund, about $216 million, added more than four percentage points to the quarter's adjusted margin. Underlying profitability sat just above twelve percent, a shade below the year-ago print. Personal Health carried the growth, Image-Guided Therapy extended a long winning streak, and China kept Precision Diagnosis in decline. Order intake dipped because large Connected Care contracts slipped a quarter, not because the backlog broke.
Guidance now embeds the refund in the full-year margin and free-cash-flow ranges while leaving comparable-sales guidance untouched. The outlook still excludes the open Department of Justice inquiry, the multi-state attorneys-general matter, and remaining Respironics proceedings. The New York Registry share sits near the bottom of its fifty-two-week range at about $25. The equity value is near $24 billion. The question for the next several quarters is whether underlying margin and China equipment demand recover without another customs windfall.